# Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

> **NCT05363631** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mohammed Milhem** · enrollment: 55 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma Metastatic

## Interventions

- **DRUG:** Selenomethionine (SLM)
- **DRUG:** Axitinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05363631
- **Lead sponsor:** Mohammed Milhem
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363631, "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05363631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*